Climara Pro Blog

Hormone Therapy May Make Lung Cancer More Likely

Posted 1 week ago by Drugs.com

SATURDAY, Sept. 19 – Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease. Read more...

Related support groups: Activella, Adgyn Estro, Aerodiol, Alora, Angeliq, Aranelle, Balziva, Bedol, Brevicon, Cenestin, Climara, Climara Pro, Climaval, Climodien, Clinagen LA 40, CombiPatch, Delestrogen, Delidose, Dep Gynogen, Depo-Estradiol, Depogen, Dermestril, Dermestril Septem, Dioval 40, Dioval XX, Divigel, Dura-Estrin, Duragen, Elestrin, Elleste Solo, Enjuvia, Esclim, Estinyl, Estra-C, Estra-V 40, Estrace, Estraderm, Estraderm MX, Estraderm TTS, Estradiol G GAM, Estradiol Patch, Estradot, Estradot 100, Estradot 37.5, Estradot 50, Estradot 75, Estragyn LA 5, Estrapatch, Estrasorb, Estreva, Estring, Estro-Cyp, Estro-LA, Estro-Span 40, Estrofem, Estrogel, Estrogen Patches, Estrostep Fe, Evamist, Evorel, Fematrix, Femcon FE, Femhrt, Fempatch, Femring, Femsept, FemSeven, FemSeven Sequi Phase I, FemTab, Femtrace, Femtran, Genora 0.5/35, Genora 1/35, Gynodiol, Gynogen LA 20, Jenest, Junel 1.5/30, Junel 1/20, Junel Fe 1.5/30, Junel Fe 1/20, Leena, Loestrin 1/20, Loestrin 21 1.5/30, Loestrin 21 1/20, Loestrin 24 Fe, Loestrin Fe 1.5/30, Loestrin Fe 1/20, Medidiol 10, Menaval-20, Menest, Menorest, Menorest Patch, Menostar, Microgestin 1.5/30, Microgestin 1/20, Microgestin FE 1.5/30, Microgestin Fe 1/20, Modicon, Necon 0.5/35, Necon 1/35, Necon 10/11, Necon 7/7/7, Nelova 0.5/35, Nelova 1/35, Nelova 10/11, Norethin 1/35 E, Norinyl 1+35, Nortrel 0.5/35, Nortrel 1/35, Nortrel 7/7/7, Nuvelle TS Phase I, Oesclim, Oestradiol, Oestradiol Implants, Oestrodose, Oestrogel, Oestrogel Pump-Pack, Ogen, Ogen 0.625, Ogen 1.25, Ogen 2.5, Organon Oestradiol, Oromone, Ortho-Est, Ortho-Novum 1/35, Ortho-Novum 10/11, Ortho-Novum 7/7/7, Ortho-Prefest, Ovcon 35, Ovcon 35 Fe, Ovcon 50, Prefest, Premarin, Premarin Intravenous, Premphase, Prempro, Primogyn Depot, Progynova, Progynova TS, Provames, Sandrena, Systen, Thais, Thaissept, Tilia Fe, Tri-Legest Fe, Tri-Norinyl, Valergen, Vivelle, Vivelle-Dot, Vivelledot, Zenchent, Zumenon, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Lung Cancer, Conjugated Estrogens, Conjugated Estrogens/Medroxyprogesterone, Drospirenone/Estradiol, Esterified Estrogens, Estradiol, Estradiol/Levonorgestrel, Estradiol/Norethindrone, Estradiol/Norgestimate, Estropipate, Ethinyl Estradiol, Ethinyl Estradiol/Norethindrone

Timing, Type of HRT May Determine Breast Cancer Risk

Posted 1 week ago by Drugs.com

WEDNESDAY, Sept. 16 – The timing and type of hormone replacement therapy women take to relieve menopausal symptoms seem to determine the degree of breast cancer risk they face, a new French study suggests.

Overall, starting estrogen-progestagen therapy soon after menopause appears to boost the risk of breast cancer, even when only used for short periods of time, according to the study, which was published in the Sept. 14 online issue of the Journal of Clinical Oncology. Read more...

Related support groups: Activella, Adgyn Estro, Aerodiol, Alora, Angeliq, Aranelle, Balziva, Bedol, Brevicon, Cenestin, Climara, Climara Pro, Climaval, Climodien, Clinagen LA 40, CombiPatch, Delestrogen, Delidose, Dep Gynogen, Depo-Estradiol, Depogen, Dermestril, Dermestril Septem, Dioval 40, Dioval XX, Divigel, Dura-Estrin, Duragen, Elestrin, Elleste Solo, Enjuvia, Esclim, Estinyl, Estra-C, Estra-V 40, Estrace, Estraderm, Estraderm MX, Estraderm TTS, Estradiol G GAM, Estradiol Patch, Estradot, Estradot 100, Estradot 37.5, Estradot 50, Estradot 75, Estragyn LA 5, Estrapatch, Estrasorb, Estreva, Estring, Estro-Cyp, Estro-LA, Estro-Span 40, Estrofem, Estrogel, Estrogen Patches, Estrostep Fe, Evamist, Evorel, Fematrix, Femcon FE, Femhrt, Fempatch, Femring, Femsept, FemSeven, FemSeven Sequi Phase I, FemTab, Femtrace, Femtran, Genora 0.5/35, Genora 1/35, Gynodiol, Gynogen LA 20, Jenest, Junel 1.5/30, Junel 1/20, Junel Fe 1.5/30, Junel Fe 1/20, Leena, Loestrin 1/20, Loestrin 21 1.5/30, Loestrin 21 1/20, Loestrin 24 Fe, Loestrin Fe 1.5/30, Loestrin Fe 1/20, Medidiol 10, Menaval-20, Menest, Menorest, Menorest Patch, Menostar, Microgestin 1.5/30, Microgestin 1/20, Microgestin FE 1.5/30, Microgestin Fe 1/20, Modicon, Necon 0.5/35, Necon 1/35, Necon 10/11, Necon 7/7/7, Nelova 0.5/35, Nelova 1/35, Nelova 10/11, Norethin 1/35 E, Norinyl 1+35, Nortrel 0.5/35, Nortrel 1/35, Nortrel 7/7/7, Nuvelle TS Phase I, Oesclim, Oestradiol, Oestradiol Implants, Oestrodose, Oestrogel, Oestrogel Pump-Pack, Ogen, Ogen 0.625, Ogen 1.25, Ogen 2.5, Organon Oestradiol, Oromone, Ortho-Est, Ortho-Novum 1/35, Ortho-Novum 10/11, Ortho-Novum 7/7/7, Ortho-Prefest, Ovcon 35, Ovcon 35 Fe, Ovcon 50, Prefest, Premarin, Premarin Intravenous, Premphase, Prempro, Primogyn Depot, Progynova, Progynova TS, Provames, Sandrena, Systen, Thais, Thaissept, Tilia Fe, Tri-Legest Fe, Tri-Norinyl, Valergen, Vivelle, Vivelle-Dot, Vivelledot, Zenchent, Zumenon, Conjugated Estrogens, Conjugated Estrogens/Medroxyprogesterone, Drospirenone/Estradiol, Esterified Estrogens, Estradiol, Estradiol/Levonorgestrel, Estradiol/Norethindrone, Estradiol/Norgestimate, Estropipate, Ethinyl Estradiol, Ethinyl Estradiol/Norethindrone

Less HRT, Fewer Cases of Possible Breast Cancer Precursor

Posted 10 weeks ago by Drugs.com

THURSDAY, Nov. 12 – Declining use of hormone replacement therapy may be driving down rates of a condition called "atypical ductal hyperplasia," a known risk factor for breast cancer, new research suggests.

This is the first time a link has been found between atypical ductal hyperplasia – abnormal cells in the breast's milk ducts – and hormone therapy, said Diana Miglioretti, senior author of a paper published in the November issue of Cancer Epidemiology, Biomarkers & Prevention.

"It sounds like another reason not to take hormones," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge. Read more...

Related support groups: Activella, Adgyn Estro, Aerodiol, Alora, Angeliq, Aranelle, Balziva, Bedol, Brevicon, Cenestin, Climara, Climara Pro, Climaval, Climodien, Clinagen LA 40, CombiPatch, Delestrogen, Delidose, Dep Gynogen, Depo-Estradiol, Depogen, Dermestril, Dermestril Septem, Dioval 40, Dioval XX, Divigel, Dura-Estrin, Duragen, Elestrin, Elleste Solo, Enjuvia, Esclim, Estinyl, Estra-C, Estra-V 40, Estrace, Estraderm, Estraderm MX, Estraderm TTS, Estradiol G GAM, Estradiol Patch, Estradot, Estradot 100, Estradot 37.5, Estradot 50, Estradot 75, Estragyn LA 5, Estrapatch, Estrasorb, Estreva, Estring, Estro-Cyp, Estro-LA, Estro-Span 40, Estrofem, Estrogel, Estrogen Patches, Estrostep Fe, Evamist, Evorel, Fematrix, Femcon FE, Femhrt, Fempatch, Femring, Femsept, FemSeven, FemSeven Sequi Phase I, FemTab, Femtrace, Femtran, Genora 0.5/35, Genora 1/35, Gynodiol, Gynogen LA 20, Jenest, Junel 1.5/30, Junel 1/20, Junel Fe 1.5/30, Junel Fe 1/20, Leena, Loestrin 1/20, Loestrin 21 1.5/30, Loestrin 21 1/20, Loestrin 24 Fe, Loestrin Fe 1.5/30, Loestrin Fe 1/20, Medidiol 10, Menaval-20, Menest, Menorest, Menorest Patch, Menostar, Microgestin 1.5/30, Microgestin 1/20, Microgestin FE 1.5/30, Microgestin Fe 1/20, Modicon, Necon 0.5/35, Necon 1/35, Necon 10/11, Necon 7/7/7, Nelova 0.5/35, Nelova 1/35, Nelova 10/11, Norethin 1/35 E, Norinyl 1+35, Nortrel 0.5/35, Nortrel 1/35, Nortrel 7/7/7, Nuvelle TS Phase I, Oesclim, Oestradiol, Oestradiol Implants, Oestrodose, Oestrogel, Oestrogel Pump-Pack, Ogen, Ogen 0.625, Ogen 1.25, Ogen 2.5, Organon Oestradiol, Oromone, Ortho-Est, Ortho-Novum 1/35, Ortho-Novum 10/11, Ortho-Novum 7/7/7, Ortho-Prefest, Ovcon 35, Ovcon 35 Fe, Ovcon 50, Prefest, Premarin, Premarin Intravenous, Premphase, Prempro, Primogyn Depot, Progynova, Progynova TS, Provames, Sandrena, Systen, Thais, Thaissept, Tilia Fe, Tri-Legest Fe, Tri-Norinyl, Valergen, Vivelle, Vivelle-Dot, Vivelledot, Zenchent, Zumenon, Conjugated Estrogens, Conjugated Estrogens/Medroxyprogesterone, Drospirenone/Estradiol, Esterified Estrogens, Estradiol, Estradiol/Levonorgestrel, Estradiol/Norethindrone, Estradiol/Norgestimate, Estropipate, Ethinyl Estradiol, Ethinyl Estradiol/Norethindrone

Skin Patches Can Cause Burns During MRIs

Posted 3+ months ago by Drugs.com

THURSDAY, March 5 – The U.S. Food and Drug Administration warned Thursday that some medication skin patches can cause burns if worn while patients undergo an MRI.

Thursday's warning applies to brand name and generic patches and those bought over-the-counter – including nicotine and pain-control patches.

Some of these patches do not include a warning that their backing contains aluminum. Although aluminum is not attracted to an MRI's magnetic field, it can conduct electricity, causing heat that can result in burns, the FDA said. Read more...

Related support groups: Climara, Climara Pro, CombiPatch, Duragesic, Duragesic-100, Duragesic-12, Duragesic-25, Duragesic-50, Duragesic-75, Emsam, Estraderm, Flector Patch, Habitrol, Menostar, Nicoderm CQ, ProStep, Vivelle, Vivelle-Dot

FDA Medwatch Alert: Transdermal Drug Patches with Metallic Backings: Risk of Burns during MRI Scans

Posted 3+ months ago by Drugs.com

[Posted 03/05/2009] FDA notified healthcare professionals and patients that certain transdermal patches (medicated patches applied to the skin), containing aluminum or other metals in the backing of the patches, can overheat during an MRI scan and cause skin burns in the immediate area of the patch. FDA is in the process of reviewing the labeling and composition of all medicated patches to ensure that those made with materials containing metal provide a warning about the risk of burns to patients who wear the patches during an MRI scan. Until this review is complete, FDA recommends that healthcare professionals referring patients to have an MRI scan identify those patients who are wearing a patch before the patients have the MRI scan. The healthcare professional should advise these patient Read more...

Related support groups: Climara, Climara Pro, CombiPatch, Duragesic, Duragesic-100, Duragesic-12, Duragesic-25, Duragesic-50, Duragesic-75, Emsam, Estraderm, Flector Patch, Habitrol, Menostar, Nicoderm CQ, ProStep, Vivelle, Vivelle-Dot

Drop in Breast Cancer Rates Due to Drop in HRT Use

Posted 3+ months ago by Drugs.com

WEDNESDAY, Feb. 4 – A new analysis shows that the drop in breast cancer cases that began in 2003 is indeed due to women stopping hormone replacement therapy (HRT) after a large, U.S. study showed surprisingly higher rates of heart problems and breast cancer among users of some kinds of HRT.

Some experts have suggested such a theory explains the trend, while others have said it might be related to changes in mammography use.

"If you stop hormones, the risk of breast cancer [associated with hormone use] rapidly declines," said Dr. Rowan Chlebowski, a medical oncologist at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of the analysis in the Feb. 5 issue of the New England Journal of Medicine. Read more...

Related support groups: Activella, Adgyn Estro, Angeliq, Aranelle, Cenestin, Climara Pro, Estinyl, Menest, Ogen, Ortho-Prefest, Premphase, Menopausal Disorders, Prevention of Breast Cancer

2 Years of Hormone Use May Be 'Safe'

Posted 3+ months ago by Drugs.com

TUESDAY, Feb. 3 – A potential two-year "safe period" for hormone replacement therapy has been identified by American Cancer Society epidemiologists, who also confirmed that using estrogen-plus-progesterone therapy increases the risk for both ductal and lobular breast cancer far more than taking estrogen alone.

The finding follows a report last month from the Society of Obstetricians and Gynaecologists of Canada that women have been needlessly scared away from using hormone therapy during menopause.

Researchers for the U.S. study followed 68,369 postmenopausal women who were cancer-free when the study began in 1992. They were followed through mid-2005. Read more...

Related support groups: Activella, Adgyn Estro, Angeliq, Aranelle, Cenestin, Climara Pro, Estinyl, Menest, Ogen, Ortho-Prefest, Premphase, Menopausal Disorders, Perimenopausal Symptoms, Postmenopausal Symptoms, Prevention of Breast Cancer

HRT Shrinks the Brain

Posted 3+ months ago by Drugs.com

MONDAY, Jan. 12 – Two studies looking at the same group of women found that while hormone therapy is linked with brain shrinkage, it does not seem to be associated with early signs of cerebrovascular disease.

This suggests that hormone therapy's effect on brain volume, not its effect on the brain lesions that indicate "silent strokes," is the mechanism by which hormones increase the risk for dementia in women over 65.

"These are a nice companion to cognitive studies reported earlier. This is now neuroradiological evidence that, together, suggest that the effect [of hormones] may be more degeneration than vascular," said Miriam Weber, an assistant professor of physical medicine and rehabilitation and of neurology at the University of Rochester Medical Center. Read more...

Related support groups: Activella, Angeliq, Climara Pro, Ortho-Prefest, Premphase, Postmenopausal Symptoms

Hormone Therapy May Cut Colorectal Cancer Risk

Posted 3+ months ago by Drugs.com

THURSDAY, Jan. 8 – Hormone therapy may lower a woman's risk of colorectal cancer, especially if she is no longer taking the hormones.

This new finding, published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, further complicates an already murky picture of the risks and benefits of hormone replacement therapy (HRT).

Previous landmark research has shown an increased risk of breast cancer and cardiovascular problems, but a lowered risk of colon cancer. More recent studies have found that the stage in life when a woman takes hormone therapy can influence the effect. The drugs are typically prescribed to women dealing with menopausal symptoms. Read more...

Related support groups: Activella, Angeliq, Climara Pro, Ortho-Prefest, Premphase, Postmenopausal Symptoms